Ignite Creation Date:
2025-12-24 @ 5:17 PM
Ignite Modification Date:
2025-12-29 @ 4:29 AM
Study NCT ID:
NCT00072150
Status:
COMPLETED
Last Update Posted:
2013-06-05
First Post:
2003-11-04
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma
Sponsor:
National Cancer Institute (NCI)
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | View |
| None | Recurrent Bladder Cancer | View |
| None | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | View |
| None | Recurrent Urethral Cancer | View |
| None | Stage III Bladder Cancer | View |
| None | Stage III Urethral Cancer | View |
| None | Stage IV Bladder Cancer | View |
| None | Stage IV Urethral Cancer | View |
| None | Transitional Cell Carcinoma of the Bladder | View |
| None | Ureter Cancer | View |
Keywords: